

# Çocuk Beslenmesindeki Yanlışların Erişkin Sağlığına Etkileri

Dr. Zerrin Önal

*İstanbul Tıp Fakültesi Çocuk Gastroenteroloji  
Hepatoloji ve Beslenme Bilim Dalı*



**14. ULUSAL  
ÇOCUK GASTROENTEROLOJİ, HEPATOLOJİ VE  
BESLENME KONGRESİ**

**12-15 MAYIS 2022  
LİMAK CYPRUS DELUXE HOTEL K.K.T.C**

*Symposium: The Effects of Childhood Diet on Adult Health and Disease*

ÖNCELİKLER  
DEĞİŞTİ





Erişkin hastalık  
etiolojisini  
anlamada yaşam  
boyu yaklaşım  
modelleri

Bebek& çocuk  
beslenmesinin kısa ve  
uzun vadeli sağlığa  
etkileri

Son yıllarda, beslenme arařtırmalarının odak noktası, beslenme ihtiyaçlarının karşılanması ve eksikliklerin önlenmesinden, beslenmenin uzun vadeli sağlık üzerindeki etkilerini anlamaya yöneldi

# Beslenme



# Doğum öncesi & sonrası beslenme Plastisite üzerine etkisi

Epidemiyologlar  
yetersiz beslenmeden  
aşırı beslenmeye doğru  
“beslenme geçişi”


## *Beslenme ve metabolik faktörler*

Sitogenez

Organogenez

Metabolik ve endokrin yanıt

Gen ekspresyonunun epigenetik  
modülasyonu





***Yaşam boyu sağlık ve hastalık riskinin metabolik  
programlanması indüklenir***

Çocukluk




Erişkin dönem





Influential factors

- Maternal factors (e.g., maternal gut microbiota, diet, obesity, diabetes)
- Neonatal and fetal factors (e.g., infections, mode of delivery, preterm birth)
- Nutritional and dietary factors (e.g., breast- and formula-feeding, weaning, Western-style diet, malnutrition)
- Lifestyle and environmental factors (e.g., exercise habits, sleep, sanitation, socioeconomic status)
- Gender
- Ethnicity
- Medication (e.g., antibiotic, proton pump inhibitors)




## Geleneksel beslenme



(Sonnenburg ED, et al. Cell Metab. 2014)

## Endüstriyel beslenme




# Endüstriyel tip beslenme


- Aşırı işlenmiş besin ve fazla fruktoz
- Fermente ve lifli besin az



- Bağırsak florası bozulur
- Mikrobiyom çeşitliliğini azalır, kompozisyonu değişir
- Barsak musin tabakası incelir
- Dolaşımda patolojik mikrobiyal ve yan ürünler artar
- Tokluk merkezi sinyallerini bozulur, sürekli açlık hali
- İnflamasyonu artışı
- Hepatosteatoz ve bağırsak geçirgenliğinde artış




## DİSBIYOZİS & KRONİK DÜŞÜK DERECELİ İNFLAMASYON



Bacteroides, proteobacteria (E.Coli, Klebsiella, Enterobacter, Acinetobacter) ↑

Bifidobacter, Lactobasillus, Enterococ, Akkermensia, Firmicutes ↓


KC KORUYUN  
BAĞIRSAĞI BESLEYİN



*Erişkin dönem & kronik hastalıklar*



# Infant Nutrition and Later Health: A Review of Current Evidence



# AS erken kesilmesi

- Emzirme, obezite, kan basıncı, dislipidemi ve diyabet riskine etkileri
- Emzirmeyi 6 aydan önce durdurmak, yaşamın ilerleyen dönemlerinde aşırı kilo ve obezite riskinde artış
- 6 aydan önce AS dışında bir süt verilmesi 20 yıl sonra obezite riskinde artış

Annals of  
**Nutrition &  
Metabolism**

Ann Nutr Metab 2014;64:262–270  
DOI: [10.1159/000365033](https://doi.org/10.1159/000365033)

Published online: October 2, 2014

## **Early Infant Feeding and Adiposity Risk: From Infancy to Adulthood**

Wendy H. Oddy<sup>a</sup> Trevor A. Mori<sup>b</sup> Rae-Chi Huang<sup>a</sup> Julie A. Marsh<sup>a</sup>  
Craig E. Pennell<sup>c</sup> Paola T. Chivers<sup>d</sup> Beth P. Hands<sup>d</sup> Peter Jacoby<sup>a</sup>  
Peter Rzehak<sup>e</sup> Berthold V. Koletzko<sup>e</sup> Lawrence J. Beilin<sup>b</sup>

## Relation of infant feeding to adult serum cholesterol concentration and death from ischaemic heart disease

- ✓ 1911-1930 /İngiltere
- ✓ 5718 E / 474 İskemik kalp hast ex
- ✓ 1381 AS+Formula
- ✓ 3733 sadece AS
- ✓ 357 sadece formula

✓ Sütten kesme yaşı  
✓ Bebek besleme yöntemi,  
✓ Yetişkin LDL kolesterol düzeyi ve iskemik kalp hastalığı ölüm oranına etkili

TABLE 1—Standardised mortality ratios for ischaemic heart disease in 5471 men born in east Hertfordshire, 1911-30, according to method of feeding as infants. (Numbers of deaths are in parentheses)

Weight at 1 year (lb)	Breast fed			Bottle fed	All
	Breast and bottle fed	Weaned at 1 year	Not weaned at 1 year		
≤18	87 (8)	93 (14)	140 (10)	126 (4)	104 (36)
-20	88 (21)	93 (39)	95 (26)	97 (6)	93 (92)
-22	90 (37)	92 (77)	121 (55)	75 (9)	97 (178)
-24	66 (22)	69 (51)	65 (21)	109 (13)	71 (107)
-26	42 (8)	67 (24)	87 (13)	104 (6)	68 (51)
>26	26 (2)	23 (3)	73 (4)	50 (1)	36 (10)
All weights	73 (98)	79 (208)	97 (129)	95 (39)	83 (474)
95% Confidence interval	59 to 89	69 to 90	81 to 115	68 to 130	75 to 90
Ratio for non-circulatory disease	74 (147)	84 (329)	85 (166)	69 (42)	81 (684)
95% Confidence interval	62 to 87	75 to 94	73 to 99	50 to 94	75 to 87

	Breast fed				All groups (No of men) (n=485)	Standard deviation
	Breast and bottle fed (n=116)	Weaned at 1 year (n=253)	Not weaned at 1 year (n=91)	Bottle fed (n=25)		
Cholesterol (mmol/l)	6.6	6.6	6.9*	7.0*	6.7 (485)	1.2
Non-fasting cholesterol (mmol/l)	6.4	6.4	6.9**	7.1**	6.5 (431)	1.2
Low density lipoprotein cholesterol (mmol/l)	4.6	4.6	5.0**	5.1*	4.7 (470)	1.1
High density lipoprotein cholesterol (mmol/l)	1.2	1.2	1.2	1.2	1.2 (470)	0.3
Low density lipoprotein:high density lipoprotein	3.8	3.8	4.2**	4.2	3.9 (470)	1.5
Triglyceride (mmol/l)†	1.4	1.4	1.5	1.4	1.4 (485)	1.6
Apolipoprotein A1 (g/l)†	1.31	1.30	1.29	1.35	1.30 (466)	1.2
Apolipoprotein B (g/l)†	1.08	1.08	1.14	1.14	1.09 (464)	1.3
Lp(a) lipoprotein (mg/l)†	92	100	96	83	97 (469)	3.6
Height (m)	1.71	1.72	1.72	1.72	1.72 (485)	0.07
Body mass index (kg/m <sup>2</sup> )	26.5	27.0	27.1	27.1	26.9 (485)	3.5
% Current smokers	23	28	27	28	27 (482)	44
% Current social class IV or V	25	24	29	24	25 (480)	43
% Social class IV or V at birth	46	48	64**	50	51 (458)	50

# AS SÜRESİ / AŞIRI KİLOLU&OBEZİTE

- 17 Çalışmanın değerlendirildiği meta analiz
- Uzun bir emzirme süresi yetişkinlikte aşırı kilo riskinde azalma ile doğrusal ilişkili
- Erişkinlikte aşırı kilolu olma riski, emzirmenin her ek ayı için %4 oranında azalmakta

TABLE 3. Duration of breastfeeding and risk of overweight: categorial analysis (random-effects model)

	Duration of breastfeeding				
	<1 month	1-3 months	4-6 months	7-9 months	>9 months
No. of duration-specific study estimates	5	14	15	11	7
Odds ratio for overweight	1.0	0.81	0.76	0.67	0.68
95% confidence interval	0.65, 1.55	0.74, 0.88	0.67, 0.86	0.55, 0.82	0.50, 0.91

- AS & endojen kolesterol sentezi üzerine etkisi yaşamın ilerleyen dönemlerinde belirginleşen regülasyon farklılıkları
- Emzirme, bebeklik döneminde TC ve LDL ↑
- Yetişkinlikte ise daha düşük seviyelerle ilişkili
- Yetişkin yaşamda AS formülasyona göre daha düşük TC
- **≥1 yıl emzirme TC&LDL seviyelerine daha iyi etkili**

TABLE 1. Continued

Reference	Year	Study Type	Source	Year Born	Age Measure	No. Breast, Bottle	Gender	Feeding Practices Recorded	Formula Type/ Comments	Exclusive Infant Feeding Groups	MD in TC mmol/L (SE)
Plancoulaine <sup>46</sup>	2000	C	From previous pre- and primary school phases	1981 to 1987	5-11 y 5-11 y	111, 131 101, 118	M F	PQ	SF	No, Br F group included those who were also FF	-0.3 (0.13) 0 (0.16)
Hodgson <sup>48</sup>	1976	C	Questionnaire respondents from a child clinic	1962 to 1965	7-12 y 7-12 y	12, 10 18, 10	M F	PQ in infancy and medical records	SF (group fed cow milk excluded)	Yes, exclusively Br F or FF for the first 3 mo	0.54 (0.34) 0.23 (0.27)
Hromadová <sup>47</sup>	1997	C	Unknown	Not stated	12-13 y	44, 13	All	In infancy	FF not stated (2 Br F groups combined)	No, exclusiveness of Br F not stated, FF group Br F for first 1 mo	-0.09 (0.27)
Ten Towns <sup>49</sup>	2001	Mixed C	School Heart Health Study	1982 to 1986	13-16 y 13-16 y	330, 289 290, 254	M F	PQ	SF	Yes, exclusively Br F or FF for the first 3 mo	0.01 (0.06) -0.05 (0.07)
Kolacek <sup>41</sup>	1993	C	Three regions of Croatia	1968 to 1969	18-23 y 18-23 y	35, 17 52, 14	M F	In infancy	27% FF, 73% fed diluted cow milk	Yes, exclusively Br F or FF for the first 3 mo	-0.2 (0.32) -0.2 (0.31)
Leeson <sup>53</sup>	2001	X	Born in a maternity hospital	1969 to 1975	20-28 y	149, 182	All	Maternal recall	SF	Yes, Br F or FF only, but minimum duration of feeding not given	-0.18 (0.11)
Marmot <sup>29</sup>	1980	C	National Survey for Health	1946	31-32 y 31-32 y	57, 20 68, 27	M F	In infancy	SF	Yes, exclusively Br F for the first 5 mo of life, FF group not Br F	-0.1 (0.25) -0.5 (0.23)
Ravelli <sup>9</sup>	2000	C	Dutch Famine Birth Cohort	1943 to 1947	48-53 y	520, 105	All	Postnatal medical records	Bottle-fed	No, FF partly Br F, feeding status recorded on average 10 d after birth	-0.16 (0.11)
Fall <sup>34</sup>	1992 1995	C	Adults born in Hertfordshire	1920 to 1930	59-70 y 60-71 y	344, 25 208, 11	M F	Birth records	FF not stated (2 Br F groups combined)	Yes, exclusively Br F or FF, Br F group divided into weaned and not weaned	-0.32 (0.25) 0.12 (0.43)


Author, year (reference)	Study design	Year of birth of subjects	Age at cholesterol measurement	Gender	Comparison groups	Mean difference total cholesterol mmol/L (SE)
Kolacek 1993 (100)	Cohort	1968-9	18-23 years	Male Female	Exclusively breastfed (n=35) vs. Formula fed (n=17) Exclusively breastfed (n=52) vs. Formula fed (n=14)	-0.2 (SE 0.3) -0.2 (SE 0.3)
Leeson 2001 (75)	Cross-sectional	1969-75	20-28 years	All	Any breastfeeding (n=149) vs. Exclusively bottle fed (n=182)	-0.18 (SE 0.0)
Marmot 1980 (30)	Cohort	1946	31-32 years	Male Female	Exclusively breastfed for 5 months (n=57) vs. Exclusively formula fed (n=20) Exclusively breastfed for 5 months (n=68) vs. Exclusively formula fed (n=27)	-0.1 (SE 0.2) -0.5 (SE 0.2)
Ravelli 2000 (77)	Cohort	1943-7	48-53 years	All	Exclusively breastfed (n=520) vs. Partly or exclusively bottle fed (n=105) in the first 10 days	-0.16 (SE 0.0)
Martin 2005 (58)	Cohort	1918-39	53-82 years	Male	Breastfed (n=272) vs. Bottle fed (n=90)	0.12 (SE 0.2)
Fall 1992 (101)	Cohort	1920-30	59-70 years	Male	Exclusively breastfed (n=344) vs. Formula fed (n=25)	-0.32 (SE 0.0)
Fall 1995 (79)	Cohort	1920-30	60-71 years	Female	Exclusively breastfed (n=208) vs. Formula fed (n=11)	0.12 (SE 0.4)

Emzirme& KB/Metaanaliz  
SKB&DKB

küçük ama önemli koruyucu etkileri

**Table 1.3.** Breastfeeding and blood pressure in later life: Random-effects meta-analyses by subgroups

Subgroup analysis	Systolic blood pressure			Diastolic blood pressure		
	Number of estimates	Mean difference (95% confidence interval)	P value	Number of estimates	Mean difference (95% confidence interval)	P value
<b>By age group</b>						
1 to 9 years	14	-1.06 (-1.70 to -0.42)	0.04	11	-0.54 (-1.27 to 0.19)	0.14
9 to 19 years	8	-1.81 (-3.13 to -0.50)	0.007	6	-0.53 (-1.22 to 0.17)	0.14
>19 years	8	-0.95 (-1.97 to 0.07)	0.07	8	-0.38 (-0.90 to 0.15)	0.16
<b>By study size</b>						
<300 participants	10	-2.45 (-3.52 to -1.38)	0.001	9	-0.87 (-1.83 to 0.08)	0.07
300-999 participants	11	-1.52 (-2.80 to -0.23)	0.02	9	-0.59 (-1.71 to 0.52)	0.30
≥1000 participants	9	-0.59 (-1.00 to -0.19)	0.004	7	-0.33 (-0.61 to -0.04)	0.02
<b>By year of birth of subjects</b>						
Before 1980	13	-1.42 (-2.44 to -0.39)	0.007	11	-0.40 (-0.78 to -0.02)	0.04
After 1980	16	-1.03 (-1.61 to -0.45)	0.001	13	-0.61 (-1.27 to 0.04)	0.06
<b>By length of recall of breastfeeding</b>						
<3 years	19	-1.23 (-1.63 to -0.82)	0.001	14	-0.59 (-0.94 to -0.23)	0.001
≥3 years	11	-1.01 (-1.97 to -0.06)	0.04	10	-0.36 (-1.02 to 0.30)	0.28
<b>By categorization of breastfeeding</b>						
Ever breastfed	14	-0.83 (-1.35 to -0.32)	0.002	13	-0.49 (-0.89 to -0.10)	0.01
Breastfed for a given number of months	16	-1.42 (-2.22 to -0.63)	0.001	12	-0.47 (-1.10 to 0.16)	0.14
<b>By control for confounding</b>						
None	11	-1.73 (-3.17 to -0.30)	0.02	9	-0.59 (-1.39 to 0.22)	0.15
Adjusted for socioeconomic status	12	-0.92 (-1.71 to -0.14)	0.02	12	-0.44 (-1.04 to 0.17)	0.16
Adjusted for socioeconomic and demographic variables	7	-1.19 (-1.70 to -0.69)	0.001	4	-0.61 (-1.12 to -0.10)	0.02
<b>Study setting</b>						
High-income country	26	-1.15 (-1.68 to -0.62)	0.001	22	-0.54 (-0.95 to -0.14)	0.009
Middle/Low-income country	4	-1.93 (-3.61 to -0.26)	0.02	3	0.13 (-1.12 to 1.37)	0.20
<b>Total</b>	<b>30</b>	<b>-1.21 (-1.72 to -0.70)</b>		<b>25</b>	<b>-0.49 (-0.87 to -0.11)</b>	



# Immediate Postnatal Growth Is Associated With Blood Pressure in Young Adulthood

## The Barry Caerphilly Growth Study

Yoav Ben-Shlomo, Anne McCarthy, Rachael Hughes, Kate Tilling,  
David Davies, George Davey Smith

✓ n: 680 /Doğum, 3.ay, 1.5 yaş, 5 yaş, 25 yaş

✓ Doğum ağırlığı ve doğum sonrası hızlı tartı alımı  
sistolik kan basıncı ile orantılı

✓ Term doğanlarda hızlı büyüme diyastolik kan basıncı  
ile de orantılı

Table 1. Basic Descriptive Data on Anthropometric Measures and Adult Blood Pressure by Gender

Variable	Men (n=362)			Women (n=318)		
	Mean	SD	Range	Mean	SD	Range
<b>Weight, kg</b>						
Birth	3.44	0.49	1.99 to 4.86	3.30	0.51	1.88 to 4.69
3.0 mo	6.42	0.73	4.10 to 8.82	5.83	0.66	3.90 to 7.64
1.5 y	12.1	1.3	8.64 to 16.3	11.3	1.2	7.88 to 14.9
5.0 y	19.1	2.3	13.5 to 31.0	18.6	2.3	11.0 to 26.4
<b>Adult measures</b>						
Age, y	25	0.7	23 to 27	25	0.7	23 to 26.8
SBP, mm Hg	123.5	11.1	100 to 169	108.0	9.4	86 to 144
DBP, mm Hg	71.5	7.6	55 to 93	68.3	7.1	53 to 102
Waist:hip ratio, ×100	83.5	5.1	71.2 to 101.8	71.2	6.0	60.6 to 95.6

Table 2. Association Between Birth Weight and Weight in Infancy and Childhood (z Score) With Adult SBP and DBP

Variables	Model 1 (n=623)†			Model 2 (n=567)			Model 3 (n=480)			Model 4 (n=474)		
	β Coefficient	95% CI	P	β Coefficient	95% CI	P	β Coefficient	95% CI	P	β Coefficient	95% CI	P
<b>SBP, mm Hg</b>												
Birth weight*	-0.94	-1.77 to -0.11	0.03	-1.61	-2.60 to -0.61	0.002	-1.47	-2.57 to -0.37	0.009	-1.22	-2.34 to -0.11	0.03
Weight at 3.0 mo	0.21	-0.60 to 1.02	0.61	0.70	-0.42 to 1.82	0.22	0.47	-0.79 to 1.72	0.46	0.37	-0.87 to 1.61	0.56
Weight at 1.5 y	0.34	-0.46 to 1.15	0.40	-0.07	-1.35 to 1.21	0.92	0.44	-0.98 to 1.85	0.55	0.29	-1.12 to 1.69	0.69
Weight at 5.0 y	0.77	-0.03 to 1.57	0.06	0.97	-0.24 to 2.19	0.12	0.76	-0.66 to 2.18	0.29	0.72	-0.68 to 2.12	0.31
<b>DBP, mm Hg</b>												
Birth weight*	-0.47	-1.06 to 0.11	0.11	-0.81	-1.51 to -0.12	0.02	-0.85	-1.63 to -0.08	0.03	-0.60	-1.38 to 0.17	0.13
Weight at 3.0 mo	0.21	-0.35 to 0.77	0.46	0.74	-0.04 to 1.53	0.06	0.56	-0.33 to 1.44	0.22	0.50	-0.37 to 1.36	0.26
Weight at 1.5 y	0.02	-0.55 to 0.58	0.96	-0.18	-1.08 to 0.73	0.70	0.07	-0.93 to 1.07	0.88	-0.04	-1.02 to 0.94	0.94
Weight at 5.0 y	0.09	-0.47 to 0.64	0.75	0.11	-0.74 to 0.97	0.79	0.11	-0.89 to 1.11	0.83	0.02	-0.95 to 1.00	0.96

# Kan Şekeri ve Tip II Diyabet

- İskelet kası değişikliklerin insülin direnci gelişiminde önemli
- Açlık glukozu iskelet kası uzun zincirli çoklu doymamış yağ asitleri ile ters orantılı
- Emzirme, iskelet kasında daha yüksek LCPUFA seviyeleri, daha düşük açlık glukozu

Owen ve ark.  
Metaanaliz /1010 çalışmadan /25 uygun/ 6 çalışma


Emzirme ve erişkin Tip 2 DM  
Emzirme ilişkili diyabetin popülasyondaki oranı %5

AS & erişkinde daha düşük insülin  
Tip 2 diyabet riskinde azalma

TABLE 2

Overall pooled differences for blood glucose, serum insulin, and odds of type 2 diabetes from studies conducted in infants, children, and adults: comparison between breastfed and formula-fed subjects<sup>†</sup>

Variable	No. of studies	No. of subjects breastfed, formula fed	Mean difference		OR of type 2 diabetes	P for difference between breastfed and formula fed	P for test for heterogeneity <sup>‡</sup>
			Blood glucose	Serum insulin			
<i>mmol/L</i>							
Glucose							
Infants	12	290, 270	-0.17 (-0.28, -0.05) <sup>†</sup>	—	—	0.005	0.169
Children and adults	7	4067, 1194	-0.01 (-0.04, 0.03)	—	—	0.679	0.245
Insulin							
Infants	7	140, 151	—	-2.86 pmol/L (-5.76, 0.04)	—	0.054	0.012
Children and adults	6	3855, 945	—	-3% (-8%, 1%)	—	0.127	0.402
Type 2 diabetes							
	7 <sup>‡</sup>	49 772, 26 972	—	—	0.61 (0.44, 0.85)	0.003	0.383
	5 <sup>‡</sup>	2579, 953	—	—	0.59 (0.40, 0.87)	0.008	0.280





## Early-Life Nutrition Interventions and Associated Long-Term Cardiometabolic Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Siran He<sup>1</sup> and Aryeh D Stein<sup>2</sup>

<sup>1</sup> Nutrition and Health Sciences Program, Laney Graduate School, Emory University, Atlanta, GA, USA; and <sup>2</sup> Rollins School of Public Health, Emory University, Atlanta, GA, USA

Review > J Am Coll Nutr. 2004 Dec;23(6 Suppl):588S-595S.

doi: 10.1080/07315724.2004.10719428.

## The developmental origins of adult disease

- ✓ AS veya düşük proteinli formülle düşük protein alımı, yaşamın ilerleyen dönemlerinde daha az obezite
- ✓ Daha hızlı erken büyüme, normal ve DDA bebeklerde insülin direnci
- ✓ ilk 6 ayda daha hızlı kilo alımı, ergenlerde metabolik risk puanı (TG, HDL, glukoz, insülin, bel çevresi, KB) artışı
- ✓ Çocukluk boyunca daha hızlı kilo alımı yetişkinlikte obezite riski

**KVH risk faktörü**

Weight (pounds)	Death from Coronary Heart Disease	
	Before 65 Years	All Ages
Birthweight:		
≤5.5 (n = 486)	1.50 (0.98 to 2.31)	1.37 (1.00 to 1.86)
-6.5 (n = 1385)	1.27 (0.89 to 1.83)	1.29 (1.01 to 1.66)
-7.5 (n = 3162)	1.17 (0.84 to 1.63)	1.14 (0.91 to 1.44)
-8.5 (n = 3308)	1.07 (0.77 to 1.49)	1.12 (0.89 to 1.40)
-9.5 (n = 1564)	0.96 (0.66 to 1.39)	0.97 (0.75 to 1.25)
≥10 (n = 731)	1.00	1.00
<i>p</i> for trend	0.001	0.005
One year old:		
≤18 (n = 715)	2.22 (1.33 to 3.73)	1.89 (1.34 to 2.66)
-20 (n = 1806)	1.80 (1.11 to 2.93)	1.58 (1.15 to 2.16)
-22 (n = 3404)	1.96 (1.23 to 3.12)	1.66 (1.23 to 2.25)
-24 (n = 2824)	1.52 (0.95 to 2.45)	1.36 (1.00 to 1.85)
-26 (n = 1391)	1.36 (0.82 to 2.26)	1.29 (0.93 to 1.78)
≥27 (n = 496)	1.00	1.00
<i>p</i> for trend	<0.001	<0.001

1924–1944 Helsinki Üniversite Hastanesi,  
n: 13 517 doğum ve çocukluk dönemi verileri

3- 11 yaş arasında VKI kontrolü  
KVH E%25, K %63 azalma

AdvNutr2021;12:461–489.

Proc Nutr Soc 2009;68(4):422-9

J Nutr 2016;146:2361– 2367

J Am Coll Nutr. 2004;23:588-595

Int J Epidemiol 2002;31(6):1235-9.

Int J Obes 2016;40:1018–1025.

Article  
**Achievement of the Targets of the 20-Year Infancy-Onset  
Dietary Intervention—Association with Metabolic Profile from  
Childhood to Adulthood**

## **STRIP ÇALIŞMASI**

199-2011  
Finlandiya/ Turku

7 ay-20 yaş /n:1062

Ateroskleroz risk  
faktörleri  
prospektif,  
randomize  
kontrollü çalışma

E & %10-15'i Pr  
%50-60'ı KH  
%30 yağ  
Kontr. G müdahale yok

Diyet hedef puanı,  
STRIP diyet  
müdahale hedefleri

- 1) SFA/  
(MUFA + PUFA) < 1:2,
- 2) SFA < %10 E
- 3) diyet lifi
- 4) sukroz alımı
- 5) diyet kolesterolü

Bebeklikten erken erişkinliğe kadar verilen diyet müdahalesi kontrol grubuna göre yağ asidlerini düzenlemekte

Diyet hedeflerine bağlılık, daha düşük kardiyo-metabolik risk

**Symposium on 'Early nutrition and later disease: current concepts, research and implications'**

**Early nutrition and long-term health: a practical approach**



- Bebek büyümesi & ateroskleroz risk faktörleri bağlantılı
- Çok hızlı bebek büyümesi
- Metabolik sendrom (bozulmuş glukoz toleransı, obezite, hipertansiyon, dislipidemi)
- Kardiyovasküler morbidite
- KVH birincil önlenmesi yaşamın ilk aylarından itibaren başlaması gerektiğini düşündürmekte

# Bebeklerin hızlı büyümesi zararlı



Hızlı erken büyüme, aterosklerotik hastalık riskini doğrudan artırmakta



Aterosklerotik sürecin erken evresi endotel disfonksiyonu, yaşamın ilk 2 haftasında ve ergenlerde en fazla

İlk haftalarda çok hızlı kilo alımı  
ilk 2 yılda ise obezite riski %60  
Erişkinlikte >%30 obezite riski




Erken büyüme hızlanmasının endotel fonksiyonu üzerindeki etkisi, yetişkinlerde sigara içmenin veya insüline bağımlı diyabetin etkisine benzer

miyokardiyal ve serebrovasküler olaylar  
insidansını azaltma

# Fazla kilolu bebek aşırı kilolu çocuk, ergen ve yetişkin olma olasılığı daha yüksek !!!!

- Erken çocuklukta daha fazla beslenme , yüksek leptin ve yüksek insülin
  - ✓ yaşamın ilerleyen dönemlerinde daha yüksek hormon konsantrasyonlarına zemin hazırlayarak tokluk sinyalleri eşiğini yükseltir
- Erken büyüme hızlanması metabolizmayı ve yağlanmayı düzenleyen hormonal eksenleri kalıcı etkilemekte
- İlk 2 yılda ve okul öncesi daha yüksek protein alımı, özellikle daha sonraki yaşlarda obezite riski
- Okul öncesi çocukların diyetini optimize etmek, daha sonraki obezitenin önlenmesi için kritik

# Fazla Protein Zararlı





Increased risk of adult obesity

**Fat restriction** -> early ↓Leptin

Long term effects

(early ↓Leptin -> Leptin resistance -> ↑ adult leptin and body fat)



**ilk 2 yıl boyunca yüksek protein alımı, yetişkinlik döneminde daha yüksek VKI**

# Erken dönem düşük yağ alımı & yetişkinlikte fazla kilolu olma


- Erken dönemde düşük ve daha sonra yüksek yağ alımı arasındaki “uyumsuzluk” obezite ve metabolik hastalıkların gelişimini teşvik
- Yaşamın erken döneminde lipid alımı ile vücut yağındaki artış arasında ters ilişki,
- ilk 2 yılda yüksek yağ tüketiminin zararlı olmadığı vurgulanmakta

Fat restriction -> early ↓Leptin

Long term effects

(early ↓Leptin -> Leptin resistance -> ↑ adult leptin and body fat)

0 2 yrs 8 yrs Adult age  
Plasticity « mismatch » Inadequate response to new challenge



## ORIGINAL ARTICLE

# Association of nutrition in early life with body fat and serum leptin at adult age



20 yıl /prospektif /n:73

- ✓ 2 yılda yağdan gelen %1'lik bir enerji artışı, 20 yaşta daha az subskapular deri kıvrım kalınlığı
- ✓ daha az yağlı kitle ve daha düşük serum leptini
- ✓ Erken yaşta yağ alımı, vücut yağı (öz.gövde) ve 20 yaşında serum leptin konsantrasyonu ile negatif ilişkili
- ✓ Erken düşük yağ alımı ileri yaşlarda aşırı kilo ve leptin direnci geliştirme duyarlılığını arttırmakta

**Table 1.** Gender-specific body characteristics and hormonal status among the 73 participants of the ELANCE French longitudinal study

	Mean (s.d.)	Mean(s.d.)	P-value <sup>a</sup>
<i>Measurement at birth</i>	<i>Boys (N = 40)</i>	<i>Girls (N = 33)</i>	
Birth weight (kg)	3.3 (0.51)	3.1 (0.5)	0.22
Length at birth (cm)	49.7 (1.7)	48.8 (2.4)	0.09
<i>Measurement at 20 years</i>	<i>Men (N = 40)</i>	<i>Women (N = 33)</i>	
<i>Anthropometry</i>			
Weight (kg)	71.9 (12.1)	56.4 (10.6)	<0.001
Height (m)	1.79 (0.06)	1.63 (0.07)	<0.001
BMI (kg m <sup>-2</sup> )	22.5 (3.7)	21.2 (3.1)	0.10
Subscapular skinfold (mm)	14.4 (7.8)	17.6 (8.5)	0.035 <sup>b</sup>
Triceps skinfold (mm)	11.9 (5.3)	17.5 (6.0)	<0.001
<i>Bioelectrical impedance analysis</i>			
Fat-free mass (kg)	62.6 (7.7)	42.9 (4.4)	<0.001
Fat mass (kg)	9.3 (5.9)	13.5 (7)	0.007
<i>Hormonal status</i>			
Leptin (μg l <sup>-1</sup> )	3.8 (3.6)	11.4 (4.1)	<0.001



- Tamamlayıcı gıdalar, beslenme açısından ihtiyaç duyulduğunda ve bebek buna hazır olduğunda emzirmeye “tamamlayıcı” olmalı
- 17- 26 hafta arası ideal
- 7-42 yıllık takip çalışmaları
- Tamamlayıcı beslenme başlama yaşı ile yağlanma riski arasında ters bir ilişki

## Timing of Introduction of Complementary Food: Short- and Long-Term Health Consequences

Hildegard Przyrembel\*

Berlin, Germany

**BMJ Open** Body mass index in school-aged children and the risk of routinely diagnosed non-alcoholic fatty liver disease in adulthood: a prospective study based on the Copenhagen School Health Records Register

- Danimarka & Kopenhag
- Prospektif
- 1930 -1989 yılları arasında doğan
- 244 464 okul çocuğu
- Okul kayıt sistemi & NAYKH kayıt sistemi
- 7 -13 yaş arasındaki VKI z-skoru, NAYKH (+) ilişkili
- 7 yaşında VKI z-skoru 1 birim artış E/K 1.15 /1.16 erişkin NAYKH

♀/♂

**Table 2** Routinely diagnosed non-alcoholic fatty liver disease given as numbers and age at diagnosis

	Men		Women	
	n	Age (years) at diagnosis given as median (5 and 95 centiles)	n	Age (years) at diagnosis given as median (5 and 95 centiles)
First incidence of non-alcoholic				
Steatosis	580	52.8 (32.0 to 69.3)	606	55.8 (38.1 to 68.4)
Steatohepatitis	428	53.9 (30.2 to 70.8)	375	54.8 (30.6 to 70.5)
Fibrosis	193	55.4 (33.4 to 71.3)	149	54.8 (35.6 to 71.1)
Cirrhosis	565	55.6 (38.0 to 70.8)	373	55.8 (40.9 to 70.5)
Total NAFLD*	1264	54.6 (32.9 to 70.3)	1106	55.8 (36.1 to 70.3)

\*The total number of non-alcoholic steatosis, steatohepatitis, fibrosis and cirrhosis is larger than the total number of NAFLD cases. The numbers of events are calculated as first incidence, thus, if an individual has more than one of the NAFLD subdiagnoses, he/she will appear in more than one of the NAFLD subcategories.  
n, number; NAFLD, non-alcoholic fatty liver disease.

Okul çağındaki çocuklarda  
VKI artışı  
yetişkin NAYKH ile ilişkili

yetişkin NAYKH gelişiminde  
çocuklukta VKI > erişkin VKI  
Daha önemli



## Body mass index in childhood and adult risk of primary liver cancer

Tina Landsvig Berentzen<sup>1</sup>, Michael Gamborg<sup>1</sup>, Claus Holst<sup>1</sup>, Thorkild I.A. Sørensen<sup>1,2</sup>, Jennifer L. Baker<sup>1,2,\*</sup>

**Background & Aims:** Childhood overweight increases the risk of early development of non-alcoholic fatty liver disease, which may predispose to carcinogenesis. We investigated if childhood body size during school ages was associated with the risk of primary liver cancer in adults.

**Methods:** A cohort of 285,884 boys and girls, born 1930 through 1980, who attended school in Copenhagen, were followed from 1977 to 31 December 2010. Their heights and weights were measured by school doctors or nurses at ages 7 through 13 years. Body mass index (BMI) z-scores were calculated from an internal age- and sex-specific reference. Information on liver cancer was obtained from the National Cancer Registry. Hazard ratios and 95% confidence intervals (95% CI) of liver cancer were estimated by Cox regression.

**Results:** During 6,963,105 person-years of follow-up, 438 cases of primary liver cancer were recorded. The hazard ratio (95% CI) of adult liver cancer was 1.20 (1.07–1.33) and 1.30 (1.16–1.46) per 1-unit BMI z-score at 7 years and 13 years of age, respectively. Similar associations were found in boys and girls, for hepatocellular carcinoma only, across years of birth, and after accounting for diagnoses of viral hepatitis, alcohol-related disorders, and biliary cirrhosis.

**Conclusions:** Higher BMI in childhood increases the risk of primary liver cancer in adults. In view of the high case fatality of primary liver cancer, this result adds to the future negative health outcomes of the epidemic of childhood overweight, reinforcing the need for its prevention.

Table 4. Hazard ratios (HR) and 95% confidence intervals (CI) of primary liver cancer and hepatocellular carcinoma in adults per 1-unit BMI z-score at each of the ages 7 through 13 years among the children without a registered diagnosis of viral hepatitis, alcohol-related disorders and biliary cirrhosis.

Characteristic	N	Primary liver cancer*		Hepatocellular carcinoma	
		Cases	HR (95% CI) <sup>†</sup>	Cases	HR (95% CI) <sup>†</sup>
BMI (kg/m <sup>2</sup> ) at 7 yr	263,532	240	1.19 (1.04 to 1.38)	143	1.17 (0.97 to 1.40)
BMI (kg/m <sup>2</sup> ) at 8 yr	267,722	244	1.21 (1.05 to 1.41)	146	1.16 (0.96 to 1.40)
BMI (kg/m <sup>2</sup> ) at 9 yr	262,629	248	1.22 (1.06 to 1.42)	146	1.15 (0.95 to 1.40)
BMI (kg/m <sup>2</sup> ) at 10 yr	257,888	250	1.30 (1.12 to 1.51)	149	1.27 (1.04 to 1.53)
BMI (kg/m <sup>2</sup> ) at 11 yr	256,222	250	1.26 (1.09 to 1.46)	151	1.24 (1.02 to 1.49)
BMI (kg/m <sup>2</sup> ) at 12 yr	253,848	249	1.30 (1.12 to 1.50)	151	1.31 (1.08 to 1.58)
BMI (kg/m <sup>2</sup> ) at 13 yr	250,300	243	1.36 (1.17 to 1.58)	146	1.39 (1.15 to 1.69)



6.963.105 kişi düzenli takip  
KC kanseri n: 438 / ort yaş 60 (30-81  
)

- ✓ okul çağında ♀/♂ VKI fazla ise
- ✓ erişkin KC kanseri riski

# Childhood body mass index and height in relation to site-specific risks of colorectal cancers in adult life


Britt W. Jensen<sup>1</sup> · Michael Gamborg<sup>1</sup> · Ismail Gögenur<sup>2</sup> · Andrew G. Renehan<sup>3</sup> · Thorkild I. A. Sørensen<sup>1,4,5</sup> · Jennifer L. Baker<sup>1,4</sup>

- 1930'dan 1972'ye kadar Kopenhag Okul Sağlığı/
- n: 257.623 çocuk
- 7-13 yaşlarında boy ve tartı takip
- Danimarka Kanser Kayıt Sistemi
- 2676 kolon + 1681 rektal adenokarsinom



**Table 4** Hazard ratios (HR) and 95% confidence intervals (CI) for associations between different patterns of change in BMI and growth in height from age 7 to 13 years and adult cancers of the colon and rectum for men and women<sup>a</sup>

	Colon			<i>p</i>	Rectum			
	HR	95% CI			HR	95% CI	<i>p</i>	
<b>BMI growth patterns</b>								
Average growth <sup>b</sup>	Reference				Reference			
Persistently heavier than average <sup>c</sup>	1.05	1.02	1.07	<0.001	0.98	0.95	1.01	0.32
Increasing BMI more than average <sup>d</sup>	1.05	1.02	1.09	0.003	1.01	0.97	1.06	0.59
Decreasing BMI from above average to average <sup>e</sup>	0.99	0.96	1.02	0.70	0.97	0.93	1.01	0.18
<b>Height growth patterns</b>								
Average growth <sup>b</sup>	Reference				Reference			
Persistently taller than average <sup>c</sup>	1.07	1.05	1.09	<0.001	1.02	0.99	1.04	0.26
Growing taller than average <sup>d</sup>	1.06	1.02	1.11	0.003	1.03	0.98	1.09	0.22
Changing from taller than average to average <sup>e</sup>	1.01	0.97	1.05	0.76	0.98	0.93	1.04	0.52



# Childhood body mass index and height and risk of histologic subtypes of endometrial cancer

J Aarestrup<sup>1</sup>, M Gamborg<sup>1</sup>, LG Ulrich<sup>2</sup>, TIA Sørensen<sup>1,3</sup> and JL Baker<sup>1,3</sup>

**BACKGROUND:** Endometrial cancer risk factors include adult obesity and taller stature, but the influence of size earlier in life is incompletely understood. We examined whether childhood body mass index (BMI; kg m<sup>-2</sup>) and height were associated with histologic subtypes of endometrial cancer.

**METHODS:** From the Copenhagen School Health Records Register, 155 505 girls born 1930–1989 with measured weights and heights from 7 to 13 years were linked to health registers. BMI and height were transformed to age-specific z-scores. Hazard ratios (HRs) and 95% confidence intervals were estimated by Cox regressions.

**RESULTS:** A total of 1020 endometrial cancers were recorded. BMI was non-linearly associated with all endometrial cancers, oestrogen-dependent cancers and the subtype of endometrioid adenocarcinomas; associations were statistically significant and positive above a z-score = 0 and non-significant below zero. Compared with a 7-year-old girl with a BMI z-score = 0, an equally tall girl who was 3.6 kg heavier (BMI z-score = 1.5) had a hazard ratio = 1.53 (95% confidence interval: 1.29–1.82) for endometrioid adenocarcinoma. BMI was not associated with non-oestrogen-dependent cancers, except at the oldest childhood ages. Height at all ages was statistically significant and positively associated with all endometrial cancers, except non-oestrogen-dependent cancers. At 7 years, per ~5.2 cm (1 z-score), the risk of endometrioid adenocarcinoma was 1.18 (95% confidence interval: 1.09–1.28). Among non-users of unopposed oestrogens, associations between BMI and endometrioid adenocarcinoma strengthened, but no effects on height associations were observed.

**CONCLUSIONS:** Endometrial carcinogenesis is linked to early-life body size, suggesting that childhood BMI and height may be useful indicators for the risk of later development of endometrial cancer and might aid in the early prevention of obesity-related endometrial cancers.


*International Journal of Obesity* (2016) **40**, 1096–1102; doi:10.1038/ijo.2016.56

**Supplementary Table 2. Childhood BMI and the risk of all endometrial cancers, oestrogen-dependent cancers and endometrioid adenocarcinomas<sup>a</sup>**

Type	Age (years)	N	Cases	BMI z-score (approximate percentile) <sup>c</sup>												P-value <sup>e</sup>		
				-1.5 (7 <sup>th</sup> )		-1.0 (16 <sup>th</sup> )		-0.5 (31 <sup>st</sup> )		0 (50 <sup>th</sup> )		0.5 (69 <sup>th</sup> )		1.0 (84 <sup>th</sup> )			1.5 (93 <sup>rd</sup> )	
				HR	95% CI	HR	95% CI	HR	95% CI	HR	95% CI	HR	95% CI	HR	95% CI		HR	95% CI
All combined	7	145 406	952	0.98	0.84-1.16	0.96	0.87-1.05	0.96	0.88-1.04	1.00 (ref.)	1.05	0.97-1.13	1.19	1.09-1.31	1.43	1.24-1.64	0.02	
	8	147 098	973	0.96	0.80-1.15	0.94	0.85-1.04	0.95	0.88-1.03	1.00 (ref.)	1.05	0.98-1.14	1.22	1.11-1.33	1.47	1.28-1.70	0.02	
	9	142 094	975	0.93	0.77-1.13	0.95	0.86-1.05	0.97	0.90-1.05	1.00 (ref.)	1.03	0.95-1.11	1.20	1.09-1.31	1.49	1.28-1.72	0.02	
	10	138 587	968	1.00	0.83-1.21	0.94	0.85-1.04	0.92	0.85-1.00	1.00 (ref.)	1.08	1.00-1.17	1.27	1.15-1.39	1.55	1.33-1.80	0.01	
	11	137 678	971	0.98	0.81-1.19	0.93	0.85-1.03	0.93	0.86-1.00	1.00 (ref.)	1.08	1.00-1.16	1.28	1.16-1.40	1.60	1.37-1.85	0.004	
	12	136 614	967	0.91	0.75-1.11	0.90	0.81-1.00	0.92	0.85-1.00	1.00 (ref.)	1.08	1.00-1.17	1.26	1.15-1.38	1.53	1.31-1.78	0.01	
	13	134 707	955	0.86	0.70-1.06	0.88	0.79-0.97	0.92	0.85-0.99	1.00 (ref.)	1.09	1.01-1.18	1.25	1.14-1.38	1.48	1.28-1.72	0.19	
Oestrogen-dependent	7	145 406	861	0.99	0.84-1.18	0.96	0.87-1.06	0.95	0.88-1.03	1.00 (ref.)	1.05	0.97-1.14	1.21	1.10-1.34	1.47	1.27-1.70	0.01	
	8	147 098	880	0.99	0.82-1.19	0.96	0.87-1.07	0.96	0.89-1.04	1.00 (ref.)	1.04	0.96-1.13	1.22	1.10-1.34	1.52	1.31-1.76	0.01	
	9	142 094	882	0.96	0.79-1.17	0.97	0.87-1.07	0.98	0.90-1.06	1.00 (ref.)	1.03	0.94-1.11	1.21	1.10-1.33	1.53	1.32-1.78	0.01	
	10	138 587	873	1.04	0.86-1.26	0.95	0.85-1.05	0.92	0.85-1.00	1.00 (ref.)	1.09	1.00-1.18	1.28	1.16-1.41	1.57	1.34-1.84	0.002	
	11	137 678	877	1.02	0.84-1.24	0.94	0.85-1.05	0.92	0.85-1.00	1.00 (ref.)	1.08	1.00-1.17	1.29	1.17-1.42	1.62	1.38-1.89	0.002	
	12	136 614	873	0.92	0.75-1.13	0.90	0.81-1.00	0.92	0.84-1.00	1.00 (ref.)	1.09	1.00-1.19	1.26	1.14-1.39	1.50	1.27-1.76	0.09	
	13	134 707	859	0.88	0.71-1.08	0.88	0.79-0.98	0.92	0.84-1.00	1.00 (ref.)	1.09	1.00-1.19	1.25	1.13-1.38	1.46	1.24-1.70	0.24	
Endometrioid adenocarcinoma	7	145 406	621	0.96	0.78-1.17	0.91	0.81-1.02	0.91	0.83-1.00	1.00 (ref.)	1.10	1.00-1.21	1.28	1.14-1.43	1.53	1.29-1.82	0.04	
	8	147 098	632	0.96	0.77-1.19	0.92	0.81-1.03	0.92	0.83-1.01	1.00 (ref.)	1.09	0.99-1.20	1.28	1.15-1.44	1.58	1.34-1.88	0.03	
	9	142 094	630	0.92	0.73-1.17	0.91	0.81-1.04	0.93	0.85-1.03	1.00 (ref.)	1.07	0.97-1.18	1.28	1.14-1.43	1.63	1.37-1.93	0.03	
	10	138 587	626	1.00	0.79-1.25	0.89	0.79-1.01	0.87	0.79-0.97	1.00 (ref.)	1.14	1.04-1.26	1.36	1.21-1.53	1.67	1.39-2.00	0.01	
	11	137 678	630	0.97	0.77-1.22	0.90	0.80-1.02	0.90	0.81-0.99	1.00 (ref.)	1.11	1.01-1.23	1.34	1.19-1.50	1.68	1.40-2.01	0.02	
	12	136 614	628	0.88	0.69-1.13	0.85	0.75-0.97	0.88	0.80-0.97	1.00 (ref.)	1.14	1.03-1.26	1.33	1.19-1.50	1.58	1.31-1.90	0.15	
	13	134 707	616	0.87	0.69-1.11	0.83	0.73-0.94	0.85	0.77-0.94	1.00 (ref.)	1.17	1.06-1.29	1.35	1.20-1.52	1.53	1.27-1.84	0.17	



# Birthweight, childhood overweight, height and growth and adult cancer risks: a review of studies using the Copenhagen School Health Records Register



3-2015)

Çocukluk&amp; VKI

mesane (geç çocukluk), kolon, endometriyum, bb, kc, özofagus (geç çocukluk), over, pankreas (<70 yaş) prostat ve tiroid

7-13 yaş çocukluk VKI & lineer büyüme Ort. fazla artış çeşitli kanser risklerini arttırmakta

# Çocukluk çağı obezitesi

Pankreas Ca

Özofagus Ca

**Causal Association of Childhood Obesity with Cancer Risk in Adulthood: A Mendelian Randomization Study**


- Çocukluk obezitesi yetişkinlikte morbidite /mortaliteyi arttırmakta
- Çocukluk yüksek VKI + genetik yatkınlık / yetişkinde kanser riski
- 24 Kanser bölgesi ile ilgili çalışmalar
- **Çocukluk VKI 1-SD'lik bir artış**
- **Yetişkinlerde pankreas kanseri riskinde %60**
- **Özofagus kanseri riskinde %47 artış riski**

Sağlıklı çocuk & ergenlik  
Erişkin Ca riskinde AZALMA



# Consumption of ultra-processed foods and cancer risk: results from NutriNet-Santé prospective cohort

Thibault Fiolet,<sup>1</sup> Bernard Srour,<sup>1</sup> Laury Sellem,<sup>1</sup> Emmanuelle Kesse-Guyot,<sup>1</sup> Benjamin Allès,<sup>1</sup> Caroline Méjean,<sup>2</sup> Mélanie Deschasaux,<sup>1</sup> Philippine Fassier,<sup>1</sup> Paule Latino-Martel,<sup>1</sup> Marie Beslay,<sup>1</sup> Serge Hercberg,<sup>1,4</sup> Céline Lavalette,<sup>1</sup> Carlos A Monteiro,<sup>3</sup> Chantal Julia,<sup>1,4</sup> Mathilde Touvier<sup>1</sup>

- 2009-2017
- n:104.940
- Prospektif kohort çalışma
- Diyetteki ultra işlenmiş gıdanın %10 artışı
- Genel kanser ve meme kanseri riskinde >%10 artış







**Table 1** Illustrative OR of MS according to BMI or serum vitamin D levels

SDS-BMI (age and gender-specific z score)	BMI at age 10 (F)	OR MS (standardised to BMI 16 at age 10 for females)
-3.5	12 (underweight)	0.53
-0.5	16 (healthy range)	1.00 (reference)
1.2	20 (overweight)	1.42
2.3	24 (obese)	1.77
Adult BMI		OR MS (standardised to OR at BMI 22.5)
18 (underweight)		0.55
22.5 (healthy range)		1.00 (reference)
27.5 (overweight)		1.96
32.5 (obese)		3.84
37.5 (morbidly obese)		7.52
Serum vitamin D (nmol/L)		OR MS (standardised to 10 nmol/L)
10 (severe deficiency)		1.00 (reference)
20 (deficiency)		0.68
40 (insufficient)		0.46
75 (sufficient)		0.33

## An exploratory study of diet in childhood and young adulthood and adult-onset multiple sclerosis



- Çocukluk/ergenlik dönemi diyeti & yetişkin MS
- Yeni başlayan MS'li yetişkin (n = 602) & kontrol(n = 653)
- %84'ü çocukluk & genç yetişkinlikte (6-10, 11-15 ve 16-20 yaş) belirli yaşlar için diyet hatırlaması sağladı
- Meyve ve yoğurt (tüm yaşlar), ve baklagil (11-15 yaş) tüketimi, daha düşük erişkin başlangıçlı MS olasılığı ( $p < 0.05$ )
- Çocukluk ve genç erişkinlik sağlıklı beslenme alışkanlıkları MS riskini azaltmakta

## Early-life famine exposure and rheumatoid arthritis in Chinese adult populations: a retrospective cohort study


- Fazla doğum ağırlığı ( $\geq 4000\text{gr}$ )
- İlk 1 yılda fazla kilolu & malnütre olma

yetişkinlikte RA gelişme riski

- Şekerli içecek tüketimi, >55 yaş seropozitif RA riskini %63 arttırmış
- Daha az kırmızı/işlenmiş et ve sodyum RA riskinde azalma

**Table 1.** Summary of the effect of early life factors on the risk of rheumatoid arthritis (RA).

Increased risk of RA	Reduced risk of RA
High birth weight	(Low birth weight)
Maternal smoking in pregnancy	Breast feeding
(Hospitalization for any infection during the first year of life)	Sharing a bedroom in childhood (reduced risk of seropositivity for RF)
	(Preterm birth)



BMJ 2021;11:e043416.

Front Med (Lausanne). 2021;689698  
Clin Exper Immunol 2010; 163: 11–16

